<DOC>
	<DOC>NCT00975182</DOC>
	<brief_summary>This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid tumors and patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen.</brief_summary>
	<brief_title>A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Documented locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable (doseescalation stage only) Documented locally advanced or metastatic NSCLC in patients who have failed at least one prior chemotherapybased regimen for incurable disease (cohortexpansion stage only) Adequate organ function as assessed by laboratory tests Evaluable disease or disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST) Agreement to use an effective form of contraception for the duration of the study Any anticancer therapy (e.g., chemotherapy, biologic therapy, or hormonal therapy) within a specified timeframe prior to first study treatment Prior treatment with PI3K pathwayinhibiting agents (cohortexpansion stage only) History of Grade &gt;= 3 fasting hyperglycemia or diabetes requiring regular medication Current clinically significant and uncontrolled systemic disease (e.g., cardiovascular, pulmonary, or metabolic) History of clinically significant cardiac or pulmonary dysfunction History of malabsorption syndrome or other condition that would interfere with enteral absorption Clinically significant history of liver disease Any condition requiring fulldose anticoagulants, such as warfarin, heparin, or thrombolytic agents Active autoimmune disease and/or need for corticosteroid therapy Known brain metastases that are untreated, symptomatic, or require therapy Pregnancy, lactation, or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PI3K</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Tarceva</keyword>
</DOC>